London — GlaxoSmithKline (GSK) is collaborating on an experimental Covid-19 vaccine with Medicago, a biotechnology company partly owned by tobacco giant Philip Morris International.

The partnership will combine Medicago’s plant-based production platform with GSK’s adjuvants — substances that enhance the body’s immune response — the companies said on Tuesday. Human testing is due to start in mid-July, and the companies aim to make the vaccine available in the first half of 2021, if it’s successful...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now